of San Diego joined forces with Allergan Inc

In fact, the San Diego company was formed in 1987 to explore the commercial potential of broad composition-of- matter patents already issued to the La Jolla Cancer Research Foundation, explained Audrey Keane, Telios' director of corporate development

of San Diego has established a cardiovascular clinical trials advisory board with Eric Topol, chairman of cardiology at the Cleveland Clinic, as its head. (c) 1997 American Health Consultants

Preclinical data with the technique were presented Friday at the International Conference on Gene Therapy of Cancer in San Diego...Founded in 1990, the San Diego company is currently testing p53 and Rb gene transfer in animal models and hopes to file an investigational new drug application in 1994

The results of a trial of 10 patients with malignant pleural effusions due to advanced lung cancer were presented by AntiCancer at the International Conference on Gene Therapy of Cancer in San Diego on Thursday...AntiCancer of San Diego received a Phase I small business innovation research grant from NCI in March to support studies to identify tumors susceptible to AC9301

Telios of San Diego is currently conducting preclinical studies of decorin in models of a variety of fibrotic conditions

of San Diego has appointed James DeCesare to its board of directors

Viagene of San Diego noted that the shares and purchase prices have been adjusted to reflect a proposed 1-for-2 reverse stock split

Another advocate for genetic medicine is Timothy Harris, vice president of research and development at Sequana Therapeutics of San Diego

He joins the San Diego company from Conner Peripherals, where he was a senior vice president. (c) 1997 American Health Consultants

Joining the board of directors of San Diego-based Corvas International Inc

Telios (NASDAQ:TLIO) of San Diego intends to study TP-9201's ability to treat acute conditions such as myocardial infarction, unstable angina and stroke

Lynn Schenk, D-Calif., and Chuck Ludlam, vice president for government affairs at the Biotechnology Industry Organization, responded to an invitation from Ira Magaziner at the CalBio Summit in San Diego (see BioWorld, Oct. 25...and Bill Otterson, director of the University of California, San Diego, Connect Program

The San Diego company (NASDAQ:CYTL) announced Tuesday that it has completed two European Phase I trials with a murine version of the monoclonal, designated CY1787

Each unit consists of one share of the San Diego company's Series A convertible preferred stock and a warrant to acquire one share of common stock (NASDAQ:GNTA

The San Diego company also released its third quarter earnings report earlier this week

of San Diego in 1989. -- Brenda Sandburg News Editor (c) 1997 American Health Consultants

Concerns that new drugs could face imposed price ceilings or sharply curtailed use under a national medical plan has been a factor in a recent slowdown in biotechnology financing, according to several speakers at the one-day conference, which was hosted by the San Diego Biocommerce Association

The one-day meeting, hosted by the San Diego Biocommerce Association, was designed to mobilize efforts to retain and nurture the health-care and bioscience industry in the state...Recalling that a study made during the double-dip recession of a decade ago had identified biotechnology as one of San Diego's best bets for economic development, Wilson told his audience that he now sees a similar state-wide role for the industry